CAN THE DEVELOPMENT OF GESTATIONAL DIABETES BE PREVENTED?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review gives the data of international studies, which reveal the properties of taurine, its effects in particular, on the development and normal functioning of a number of organs and systems in both experimental animals and man during pregnancy. It describes the antitoxic and antioxidant effects of taurine on the processes involved in the intrauterine formation of carbohydrate metabolism and on the proven mechanisms of action of taurine on the processes of endocrine pancreas maturation, as well as CNS neurogenesis. The benefits of taurine successfully used to treat type 2 diabetes mellitus and metabolic disturbances in human polycystic ovary syndrome are discussed. There is evidence for the efficacy and safety of taurine used as a modulator of carbohydrate metabolism in clinical and experimental studies and the established positive effect of the agent on the processes of endocrine pancreas formation and on the birth of healthy animal descendants is discussed. The authors conclude that the available data give grounds to conduct clinical trials in the population of pregnant women who have risk factors for gestational diabetes (GD) since taurine can become a means for the primary prevention of GD and gestosis and give birth to a healthy baby even with a fam ily history of diabetes mellitus.

Full Text

Restricted Access

About the authors

T. A ZYKOVA

North State Medical University, Ministry of Health of the Russian Federation

Email: tatyana@atnet.ru

N. V MALEIKOV

North State Medical University, Ministry of Health of the Russian Federation

I. A MILAVKINA

North State Medical University, Ministry of Health of the Russian Federation

References

  1. Аметов А.С., Кочергина И.И. Применение Дибикора при сахарном диабете 2 типа и сердечно-сосудистой патологии // Эффективная фармакотер. и эндокринол. - 2007. - № 2. - С. 40-49.
  2. Бондарь И.А., Шабельникова О.Ю., Алина А.Р. Антиоксидант Дибикор в лечении сосудистых осложнений сахарного диабета 2-го типа // Пробл. эндокринол. - 2009. - Т. 55, № 2. - С. 41-45.
  3. Ворохобина Н.В., Кузнецова А.В. Применение Дибикора у больных сахарным диабетом 2-го типа и метаболическим синдромом // Рус. мед. журн. - 2010. - Т. 18, № 30. - С. 1816-1819.
  4. Захаров И.В. Оптимизация терапии артериальной гипертензии у беременных // Вопр. гин., акуш. и перинатол. - 2010. - Т. 9, № 5. - С. 10-13.
  5. Зыкова Т.А., Стрелкова А.В., Зыков И.Н., Уледева Л.В. Изменения метаболизма и состояние репродуктивной функции при использовании Дибикора у женщин с синдромом поликистозных яичников // Фарматека. - 2010. - № 3. - С. 79-86.
  6. Крючкова И.В., Адамчик А.С. Возможности коррекции нарушений углеводного обмена при метаболическом синдроме // Рос. кардиол. журн. - 2009. - № 2. -С. 44-48.
  7. Кудинов В.И., Золотарева И.В., Корсун. Н.А. и др. Изучение клинической эффективности Дибикора при сахарном диабете 2 типа // Сборник материалов XIV Российского национального конгресса «Человек и лекарство»: Тезисы докладов. - М., 2007. - С. 129.
  8. Мкртумян А.М., Подачина С.В., Петраченко В.В. Дибикор - эффективное и безопасное средство для лечения сахарного диабета // Эффективная фармакотер. в эндокринол. - 2008. - № 2. - С. 34-39.
  9. Недосугова Л.В., Котешкова О.М., Балаболкин М.И. Применение Дибикора при сахарном диабете // Фарматека. - 2006. - № 3. - С. 134-137.
  10. Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш. Опыт применения Дибикора при сахарном диабете 2 типа // Сахарный диабет. - 2007. - № 1. - С. 30-31.
  11. Arany E., Strutt B., Romanus P. Taurine supplement in early life altered islet morphology, decreased insulitis and delayed the onset of diabetes in non-obese diabetic mice // Diabetologia. - 2004. - Vol. 47, № 10. - P. 1831-1837.
  12. Thanasiadis A.P., Michaelidou A.M., Fotiou M. et al. Correlation of 2nd trimester amniotic fluid amino acid profile with gestational age and estimated fetal weight // J. Matern. Fetal Neonatal Med. - 2011. - Vol. 24, № 8. - P. 1033-1038.
  13. Boujendar S., Reusens B., Merezak S. et al. Taurine supplementation to a low protein diet during foetal and early postnatal life restores a normal proliferation and apoptosis of rat pancreatic islets // Diabetologia. - 2002. - Vol. 45, № 6. - P. 856 -866.
  14. Boujendar S., Arany E., Hill D. et al. Taurine supplementation of a low protein diet fed to rat dams normalizes the vascularization of the fetal endocrine pancreas // J. Nutr. -2003. - Vol. 133, № 9. - P. 2820-2825.
  15. Brown L.D., Green A.S., Limesand S.W., Rozance P.J. Maternal amino acid supplementation for intrauterine growth restriction // Front. Biosci. (Schol Ed). - 2011. - Vol. 3. -P. 428-444.
  16. Chen H., Li J., Liu J. et al. Effects of prenatal taurine on mRNA expression of PKA CREB signal pathway and glial cell line derived neurotrophic factor in fetal rat brains of intrauterine growth restriction // Zhongguo Dang Dai Er Ke Za Zhi. - 2009. - Vol. 11, № 11. - 923-926.
  17. Gurekian C.N., Koski K.G. Amniotic fluid amino acid concentrations are modified by maternal dietary glucose, gestational age, and fetal growth in rats // J. Nutr. - 2005. -Vol. 135, № 9. - P. 2219-2224.
  18. Hoet J.J., Ozanne S., Reusens B. Influences of pre- and postnatal nutritional exposures on vascular/endocrine systems in animals // Environ. Health Perspect. - 2000. - Vol. 108, № 3 (Suppl). - P. 563-568.
  19. Lee N.Y., Kang Y.S. Regulation of taurine transport at the blood-placental barrier by calcium ion, PKC activator and oxidative stress conditions // J. Biomed. Sci. - 2010. -Vol. 24, № 17. (Suppl 1.). - P.S 37. 06.
  20. Lee N.Y., Lee H.J., Lee S.S. Тaurine supplementation restored the changes in pancreatic islet mitochondria in the fetal protein-malnourished rat // Br. J. Nutr. - 2011. -Vol. 106 - № 8. - P. 1198-12
  21. Lemons J.A. Fetal-placental nitrogen metabolism // Semin. Perinatol. - 1979. - Vol. 3. - P. 177-190.
  22. Li H., Han L., Zhao D. Effect of zinc L-lysine and taurine against teratogenesis caused by hyperthermia // Zhonghua Yi Xue Za Zhi. - 2002. - Vol. 82, № 10. - P. 682-684.
  23. Mao D.W., Zhao Y.P., Li S.R. et al. Study of teratogenicity of hyperglycemia on neural tube defects and antagonistic effect of taurine // Zhonghua Fu Chan Ke Za Zhi. - 2004. -Vol. 39, № 3. - P. 169-172.
  24. Merezak S., Hardikar A.A., Yajnik C.S. et al. Intrauterine low protein diet increases fetal beta-cell sensitivity to NO and IL-1 beta: the protective role of taurine // J. Endocrinol. - 2001. - Vol. 171, № 2. - P. 299-308.
  25. Merezak S., Reusens B., Renard A. et al. Effect of maternal low-protein diet and taurine on the vulnerability of adult Wistar rat islets to cytokines // Diabetologia. - 2004. -Vol. 47, № 4. - P. 669-675.
  26. Mortensen O.H., Olsen H.L., Frandsen L. et al. A maternal low protein diet has pronounced effects on mitochondrial gene expression in offspring liver and skeletal muscle; protective effect of taurine // J. Biomed. Sci. - 2010. - Vol. 24, № 17 (Suppl. 1). - P. 38.
  27. Petrik J., Arany E., McDonald T.J., Hill D.J. Apoptosis in the pancreatic islet cells of the neonatal rat is associated with a reduced expression of insulin-like growth factor II that may act as a survival factor // Endocrinology. - 1998. -Vol. 139. - P. 2994-3004.
  28. Reusens B., Sparre T., Kalbe L. et al. The intrauterine metabolic environment modulates the gene expression pattern in fetal rat islets: prevention by maternal taurine supplementation // Diabetologia. - 2008. - Vol. 51, № 5. -P. 836-845.
  29. Reusens B., Theys N., Dumortier O. et al. Maternal malnutrition programs the endocrine pancreas in progeny // Am. J. Clin. Nutr. - 2011. - Vol. 94, № 6 (Suppl.). -P. 1824S-1829S.
  30. Seghieri G., Tesi F., Bianchi L. et al. Taurine in women with a history of gestational diabetes // Diabet. Res. Clin. Pract. - 2007. - Vol. 76, № 2. - P. 187-192.
  31. Velazquez A., Rosado A., Bernal A. et al. Amino acid pools in the feto-maternal system // Biol. Neonate. - 1976. -Vol. 29. - P. 28-40.
  32. Zumsteg U., Fvigerio S., Hollander G.A. Nitric oxide production and Fas surface expression mediate two independent pathways of cytokine-induced murine beta-cell damage // Diabetes. -2000. - Vol. 49. - P. 39-47.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies